Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: SMI of Bcl-2 TW-37 is active across a spectrum of B-cell tumors irrespective of their proliferative and differentiation status | BioMed Central Journal of Hematology Oncology Research SMI of Bcl-2 TW-37 is active across a spectrum of B-cell tumors irrespective of their proliferative and differentiation status Ayad M Al-Katib Yuan Sun Anton Scott Goustin Asfar Sohail Azmi Ben Chen Amro Aboukameel and Ramzi M Mohammad Address Department of Internal Medicine Division of Hematology Oncology Wayne State University School of Medicine Detroit Michigan USA Email Ayad M Al-Katib - alkatib@ Yuan Sun - ysun@ Anton Scott Goustin - ad5226@ Asfar Sohail Azmi - azmia@ Ben Chen - chenb@ Amro Aboukameel - kameelo@ Ramzi M Mohammad - mohammar@ Corresponding author Open Access Published 16 February 2009 Journal of Hematology Oncology 2009 2 8 doi 1 756-8722-2-8 Received 2 October 2008 Accepted 16 February 2009 This article is available from http content 2 1 8 2009 Al-Katib et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract The Bcl-2 family of proteins is critical to the life and death of malignant B-lymphocytes. Interfering with their activity using small-molecule inhibitors SMI is being explored as a new therapeutic strategy for treating B-cell tumors. We evaluated the efficacy of TW-37 a non-peptidic SMI of Bcl-2 against a range spectrum of human B-cell lines fresh patient samples and animal xenograft models. Multiple cytochemical and molecular approaches such as acridine orange ethidium bromide assay for apoptosis co-immunoprecipitation of complexes and western blot analysis caspase luminescent activity assay and apoptotic DNA fragmentation assay were used to demonstrate the
